ELVN

+ Watchlist + Portfolio

Enliven Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $59.39
52-Week Range: $14.79 – $62.32
Market Cap: $4.32B
P/E (TTM): —
EPS (TTM): -1.65
Dividend Yield: —

Advanced Metrics

Price/Book: 4.82
PEG Ratio: —
Return on Equity: -15.31%
Return on Assets: -11.00%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 64.07
Debt/Equity: 0.00
Total Debt: $1.51M
Free Cash Flow: $-45.26M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $3.46B

ELVN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$31.02M	$64.57M	$80.78M	$85.86M
Selling, General & Admin	$7.77M	$18.95M	$23.78M	$33.80M
Operating Expenses	$38.79M	$83.53M	$104.55M	$119.66M
Operating Income	-$38.79M	-$83.53M	-$104.55M	-$119.66M
EBITDA	-$38.58M	-$83.23M	-$104.24M	-$119.39M
Pretax Income	-$37.66M	-$71.58M	-$88.79M	-$103.69M
Income Tax	—	$0.00	$232.00K	$0.00
Net Income	-$37.66M	-$71.58M	-$89.02M	-$103.69M
Diluted EPS	-0.92	-2.01	-1.89	-1.83
Diluted Shares	41.10M	35.55M	47.07M	56.66M

ELVN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$75.54M	$100.14M	$124.12M	$98.90M
Current Assets	$77.75M	$266.15M	$318.13M	$474.88M
Total Assets	$83.30M	$271.87M	$325.76M	$476.17M
Current Liabilities	$9.71M	$25.89M	$15.91M	$16.57M
Total Debt	$323.00K	$335.00K	$0.00	$399.00K
Total Liabilities	$160.12M	$25.96M	$15.91M	$16.57M
Retained Earnings	-$82.86M	-$154.45M	-$243.47M	-$347.17M
Shareholders' Equity	-$76.83M	$245.91M	$309.85M	$459.60M
Working Capital	$68.04M	$240.26M	$302.21M	$458.31M

ELVN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$32.08M	-$61.27M	-$73.19M	-$70.30M
Capital Expenditure	-$612.00K	-$149.00K	-$44.00K	-$158.00K
Free Cash Flow	-$32.69M	-$61.42M	-$73.24M	-$70.46M
Depreciation & Amortisation	$215.00K	$297.00K	$317.00K	$263.00K
Stock-Based Compensation	$3.19M	$12.91M	$20.17M	$34.02M
Investing Cash Flow	-$612.00K	-$148.41M	-$36.00M	-$173.84M
Financing Cash Flow	-$1.80M	$234.29M	$133.16M	$218.87M
Net Change in Cash	-$34.49M	$24.61M	$23.98M	-$25.27M

ELVN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$24.89M	$21.49M	$18.23M	$21.25M	$20.69M
Selling, General & Admin	$6.80M	$7.09M	$6.87M	$13.04M	$7.14M
Operating Expenses	$31.69M	$28.58M	$25.10M	$34.28M	$27.82M
Operating Income	-$31.69M	-$28.58M	-$25.10M	-$34.28M	-$27.82M
EBITDA	-$31.62M	-$28.50M	-$25.03M	-$34.24M	-$27.81M
Pretax Income	-$28.54M	-$25.34M	-$20.15M	-$29.67M	-$23.63M
Income Tax	—	$0.00	$0.00	$0.00	—
Net Income	-$28.54M	-$25.34M	-$20.15M	-$29.67M	-$23.63M
Diluted EPS	-0.57	-0.49	-0.32	-0.48	-0.38
Diluted Shares	50.05M	52.10M	62.09M	62.21M	62.80M

ELVN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$101.70M	$119.44M	$101.73M	$98.90M	$132.18M
Current Assets	$294.32M	$495.62M	$482.68M	$474.88M	$463.14M
Total Assets	$302.57M	$503.89M	$490.88M	$476.17M	$464.85M
Current Liabilities	$13.97M	$15.21M	$14.65M	$16.57M	$11.49M
Total Debt	$365.00K	$580.00K	$387.00K	$399.00K	$302.00K
Total Liabilities	$14.27M	$15.41M	$14.75M	$16.57M	$11.49M
Retained Earnings	-$272.02M	-$297.35M	-$317.50M	-$347.17M	-$370.79M
Shareholders' Equity	$288.30M	$488.47M	$476.12M	$459.60M	$453.37M
Working Capital	$280.35M	$480.41M	$468.03M	$458.31M	$451.65M

ELVN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$24.13M	-$17.06M	-$13.28M	-$15.84M	-$19.29M
Capital Expenditure	-$20.00K	-$139.00K	—	—	—
Free Cash Flow	-$24.15M	-$17.20M	-$13.28M	-$15.84M	-$19.29M
Depreciation & Amortisation	$74.00K	$81.00K	$62.00K	$46.00K	$14.00K
Stock-Based Compensation	$6.80M	$7.72M	$7.18M	$12.31M	$7.40M
Investing Cash Flow	$1.43M	-$183.59M	-$4.06M	$12.38M	$42.53M
Financing Cash Flow	$234.00K	$218.38M	-$368.00K	$623.00K	$10.05M
Net Change in Cash	-$22.47M	$17.73M	-$17.70M	-$2.84M	$33.29M

Market Snapshot

About

Enliven Therapeutics is a clinical-stage precision oncology company focused on developing small molecule kinase inhibitors for the treatment of cancer. The company's lead program targets patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) harboring specific genetic mutations. Enliven's pipeline includes novel BCR-ABL1 tyrosine kinase inhibitors designed to overcome resistance mechanisms that limit the effectiveness of current therapies. The company's precision medicine approach aims to develop therapies matched to specific patient populations based on genetic biomarkers.